CG Oncology (CGON) Short Interest & Short Float | Updated Sep 2026
CG Oncology (CGON) had a short interest of 11.25 million shares as of September 15, 2026, representing 13.34% of its public float, which is a 1.24% decrease from the previous report. The short interest ratio is 17.0 days to cover, indicating strong pessimism about the stock. This report provides historical short interest data, frequently asked questions, and comparisons to competitors in the biotechnology industry.
After $7.9M sale, CG Oncology (NASDAQ: CGON) officer plans more stock trades
CG Oncology (NASDAQ: CGON) officer Ambaw Bellete has filed a Rule 144 notice indicating an intended sale of 30,787 shares of common stock, tied to a stock option exercise, with Morgan Stanley Smith Barney LLC handling the transaction on NASDAQ. The filing also reveals numerous prior sales by Bellete over the past three months, including a significant sale of 100,000 shares on August 19, 2026, valued at over $7.9 million. These transactions highlight insider activity and potential market impact for CGON investors.
CG Oncology (NASDAQ: CGON) officer sold 100,000 shares and now plans more
An officer at CG Oncology (CGON), Ambaw Bellete, has filed a Rule 144 notice to sell 6,532 shares of common stock, valued at approximately $499,698, after previously selling 100,000 shares for over $7.9 million on August 19, 2026. The filing indicates a stock option exercise and multiple other significant sales by Bellete in the past three months, alongside the company's reported 88,640,375 shares outstanding. This proposed sale will be executed through Morgan Stanley Smith Barney.
CG Oncology (NASDAQ: CGON) director sells shares under preset trading plan
CG Oncology director Leonard E. Post exercised options for 1,000 shares and simultaneously sold them at a weighted average price of $72.98 under a pre-arranged Rule 10b5-1 trading plan. The transaction resulted in an approximate pre-tax spread of $72,000. Following these transactions, Post directly held 103,077 option-based rights.
CG Oncology at Cantor conference: cretostimogene nears key readout
CG Oncology discussed its lead drug, cretostimogene, for non-muscle invasive bladder cancer (NMIBC) at the 12th Annual Cantor Fitzgerald Global Healthcare Conference. The company is nearing a key Phase III readout for intermediate-risk NMIBC, advancing manufacturing for its initial BLA, and planning a third Phase III trial for BCG-exposed high-risk disease. Despite strong clinical progress, the company acknowledges market competition and the need to demonstrate real-world adoption, with financial profitability not expected until after 2026.
Planned CG Oncology (NASDAQ: CGON) insider sale totals 826 shares
An officer at CG Oncology (NASDAQ: CGON), Ambaw Bellete, plans to sell 826 shares of common stock for $61,950 on September 11, 2026, following a stock option exercise. This information comes from a Rule 144 SEC filing. The filing also details numerous prior sales by Bellete over the preceding three months, including a 100,000-share sale for over $7.9 million on August 19, 2026.
Bank of New York Mellon Corp Invests $16.58 Million in CG Oncology, Inc. $CGON
Bank of New York Mellon Corp has acquired a new stake of 233,419 shares in CG Oncology, Inc. (NASDAQ:CGON), valued at approximately $16.58 million, representing 0.26% of the company. Institutional investors collectively own 26.56% of CG Oncology. Despite insider activity showing both buying and selling, and the company missing its quarterly EPS estimate, analysts maintain a consensus "Moderate Buy" rating with an average price target of $83.18.
CG Oncology, Inc. $CGON Shares Sold by Wellington Management Group LLP
Wellington Management Group LLP reduced its stake in CG Oncology (NASDAQ:CGON) by 0.9% in Q2 2026, selling 46,481 shares but still holding 5.32 million shares worth $378.3 million. Analyst sentiment for CGON is largely positive, with a "Moderate Buy" consensus and an average price target of $83.18. The company reported a Q2 loss of $0.90 per share, missing estimates, but revenue exceeded expectations.
Man Group plc Takes $3.68 Million Position in CG Oncology, Inc. $CGON
Man Group plc has acquired a significant position in CG Oncology, Inc. (NASDAQ:CGON), purchasing 51,849 shares valued at approximately $3.68 million in the second quarter. This investment makes Man Group plc an approximate 0.06% owner of the company, highlighting institutional interest in the biopharmaceutical firm. Despite the company reporting a quarterly loss that missed analyst estimates, its revenue exceeded expectations, and analysts maintain a "Moderate Buy" consensus with an $83.18 price target.
California loses another multibillion-dollar company to Texas
Biotech company CG Oncology, valued at $7 billion, has moved its headquarters from Irvine, California, to Dallas, Texas, signing an eight-year lease at Pegasus Park. The company, which focuses on bladder cancer immunotherapy, cited better access to talent and new facilities as reasons for the relocation. This move follows a trend of other California-headquartered companies relocating to Texas.
CG Oncology, Inc. $CGON Shares Purchased by Algert Global LLC
Algert Global LLC significantly increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 140.9% in the second quarter, bringing its total to 46,690 shares valued at approximately $3.3 million. The article also details mixed insider activity, including a major director purchase and sales, and notes that institutional investors collectively own 26.56% of the company. Despite missing analyst EPS estimates for the last quarter, CG Oncology's revenue exceeded forecasts, and analysts maintain a "Moderate Buy" consensus rating with an $83.18 price target.
BlackRock Inc. Buys New Shares in CG Oncology, Inc. $CGON
BlackRock Inc. has acquired a significant new position in CG Oncology, Inc. (NASDAQ:CGON), purchasing over 6.26 million shares valued at approximately $444.5 million, representing 7.09% of the company. Other institutional investors have also increased their stakes in CGON, contributing to a total institutional ownership of 26.56%. Despite reporting a larger-than-expected loss per share in its latest quarter, analysts maintain a "Moderate Buy" rating for CGON, with an average price target of $83.18.
ADAR1 Capital Management LLC Invests $8.43 Million in CG Oncology, Inc. $CGON
ADAR1 Capital Management LLC has acquired 118,664 shares of CG Oncology, Inc. (NASDAQ:CGON) for approximately $8.43 million, establishing a new position in the clinical-stage biopharmaceutical company. Despite this institutional investment and a "Moderate Buy" consensus rating from analysts, CG Oncology recently missed its quarterly earnings expectations. The company's stock opened at $78.95, near its 52-week high, with institutional investors collectively owning 26.56% of the shares.
Another California giant bolts for Texas as multi-billion-dollar company announces move
CG Oncology, a $7 billion Nasdaq-traded biotech firm focused on bladder cancer treatments, has moved its corporate headquarters from Irvine, California, to Dallas, Texas. The company cited access to talent, investors, strategic partners, and cost advantages in Dallas's growing life sciences ecosystem. This move is part of a larger trend of companies, including major names like Tesla and Oracle, relocating from California due to high corporate taxes, regulations, and living costs.
CG Oncology (NASDAQ: CGON) officer eyes new sale after $7.9M August stock trade
An officer at CG Oncology (NASDAQ: CGON), Ambaw Bellete, has filed a Form 144 indicating an intention to sell 10,551 shares of common stock on or about August 25, 2026, following a stock option exercise. This planned sale is valued at approximately $839,338.38. The filing also details numerous prior sales by Bellete in July and August 2026, including a significant transaction of 100,000 shares for over $7.9 million on August 19, 2026.
CG Oncology (NASDAQ: CGON) officer plans new sale after $7.95M August trade
Ambaw Bellete, an officer at CG Oncology, Inc. (CGON), has filed a Form 144 notice indicating a proposed sale of 5,762 shares of common stock following a stock option exercise. This follows several significant sales by Bellete in the past three months, including transactions totaling $7.95 million on August 19, 2026, and $5.67 million on August 6, 2026. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ exchange.
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
Kuehn Law, PLLC is investigating whether certain officers and directors of CG Oncology, Inc. (NASDAQ: CGON) breached their fiduciary duties to shareholders, specifically concerning potential self-dealing. The firm encourages long-term CGON stockholders to contact them to discuss potential damages and corporate governance reforms. The consultation and case are free, with Kuehn Law covering all case costs.
How Investors May Respond To CG Oncology (CGON) Revenue Growth Alongside a Widening Net Loss
CG Oncology (CGON) recently reported Q2 results with increased revenue but a widening net loss, highlighting its status as a research-driven company. The investment narrative centers on cretostimogene's clinical profile justifying heavy investment, with clinical trial readouts being key catalysts. Despite rising share prices, growing cash burn and financing risk are significant concerns for investors, leading to varied fair value estimates.
Investigation launched into CG Oncology officers for possible self-dealing harming shareholders
Kuehn Law, PLLC has launched an investigation into officers and directors of CG Oncology, Inc. for potential self-dealing and breaches of fiduciary duties. The probe aims to determine if shareholder rights have been violated, which could lead to damages and changes in corporate governance. Long-term investors are encouraged to contact the firm as there may be a limited timeframe for action.
How Investors May Respond To CG Oncology (CGON) Revenue Growth Alongside a Widening Net Loss
CG Oncology (CGON) reported Q2 results showing increased revenue of US$1.16 million, but also a widening net loss of US$79.06 million, indicating it remains a research-driven company. The investment narrative hinges on the success of its drug cretostimogene, with clinical trial readouts being key catalysts despite escalating cash burn and financing risks. While the stock has seen a strong year-to-date run, the growing losses and varied fair value estimates suggest a high degree of uncertainty among investors.
CG Oncology stock hits all-time high of 79.5 USD By Investing.com
CG Oncology's stock reached an all-time high of $79.50, trading just below its 52-week high with a 1-year return of 198% and 84% year-to-date gains. Despite strong investor confidence, InvestingPro analysis suggests the stock is overvalued and the company remains unprofitable, with analysts not expecting profitability this year. Recent positive Phase 3 trial results and subsequent analyst reports from H.C. Wainwright (Buy rating, $100 target) and Wolfe Research (Peerperform rating) highlight ongoing interest and varied expectations for the company's cretostimogene product.
CG Oncology (NASDAQ: CGON) insider flags $7.95M stock sale after recent disposals
An officer at CG Oncology, Ambaw Bellete, has filed a Rule 144 notice to sell up to 100,000 shares of the company's common stock, valued at approximately $7.95 million. This filing also details recent stock option exercises for 100,000 shares and significant open-market sales by Bellete totaling over $9 million in the past three months. The shares are expected to be sold through Morgan Stanley Smith Barney LLC.
CG Oncology stock hits all-time high of 79.5 USD
CG Oncology Inc.'s stock reached an all-time high of $79.50, driven by a 198% one-year return and 84% year-to-date gains. Despite this performance, InvestingPro analysis indicates the stock may be overvalued and the company is not yet profitable. Analysts have issued mixed ratings following positive Phase 3 trial results, with H.C. Wainwright reiterating a Buy while Wolfe Research initiated with a Peerperform rating.
CG Oncology stock hits all-time high of 79.5 USD By Investing.com
CG Oncology Inc.'s stock reached an all-time high of 79.5 USD, trading just below its 52-week high with a 1-year return of 198% and 84% year-to-date gains. Despite this impressive growth, InvestingPro analysis suggests the stock is overvalued, and the company remains unprofitable according to analysts. Recent developments include positive Phase 3 trial results published in Lancet Oncology and varied analyst ratings, reflecting ongoing interest and mixed expectations for the company's future.
CG Oncology (CGON) director sells 1,000 shares at $74.54
CG Oncology (CGON) director Leonard E. Post exercised a fully vested stock option for 1,000 shares at $0.60 per share and subsequently sold those 1,000 shares at $74.54 each on August 14, 2026. This transaction was conducted under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following the sale, Post holds 104,077 director stock options directly.
CG Oncology (NASDAQ: CGON) insider lines up new stock sale
CG Oncology insider Ambaw Bellete has filed a Form 144 notice to sell 52,438 shares of common stock, valued at approximately $4.0 million, through Morgan Stanley Smith Barney LLC on August 17, 2026. This planned sale is linked to a stock option exercise. The filing also reveals that Bellete has made several previous open-market sales of CGON common stock in the past three months, including sales of 75,000 shares and multiple 50,000-share transactions.
CG Oncology (CGON) sees Foresite Capital report 4.9% beneficial stake via funds
Foresite Capital funds and James B. Tananbaum have reported beneficial ownership in CG Oncology (CGON) via a SCHEDULE 13G/A filing. While individual funds hold stakes under 5%, James B. Tananbaum, managing member of the involved Foresite Capital entities, is deemed to beneficially own 4,306,174 shares, representing 4.9% of CG Oncology's outstanding common stock. This aggregated stake is based on 88,640,375 shares outstanding as of August 4, 2026.
CG Oncology (CGON): RTW Investments takes 9.7% position, holding 8.5M shares
RTW Investments, LP and Roderick Wong, M.D. have reported a 9.7% beneficial ownership in CG Oncology, Inc. (CGON), totaling 8,514,590 common shares. These shares are held by RTW-managed funds, with RTW Investments and Dr. Wong sharing voting and dispositive power. The ownership percentage is based on 88,202,473 shares outstanding as of May 6, 2026.
CG Oncology's bladder cancer drug shows strong results with 75% response rate and no severe side effects.
CG Oncology's experimental drug cretositimogene grenadenorepvec (cret) has shown promising results in treating non-muscle invasive bladder cancer (NMIBC), achieving a 75% complete response rate and demonstrating a best-in-class safety profile with no severe adverse events. The company plans to submit a Biologics License Application (BLA) by Q4 2026. This positive progress has led to a significant increase of over 150% in CG Oncology's share price over the past year.
CGON (CGON) investor lists 25,989-share sale after series of stock disposals
An investor in CG Oncology, Inc. (CGON) has filed a Form 144, indicating a planned sale of 25,989 common shares with an aggregate market value of $1,973,970.86, expected on August 13, 2026. This filing also discloses a series of prior open-market sales by Ambaw Bellete over the last three months, including a significant transaction of 75,000 shares for $5,672,212.50 on August 6, 2026. The planned sale involves shares related to a stock option exercise and will be handled by Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ.
CG Oncology (CGON): Wellington group discloses 5.3M-share, 6.04% ownership position
A group of affiliated Wellington entities has disclosed a beneficial ownership of 5,324,751 shares of CG Oncology (CGON) common stock, representing 6.04% of the class. This disclosure, filed via a SCHEDULE 13G/A, indicates shared voting power over 4,637,354 shares and shared dispositive power over all 5,324,751 shares. The shares are held by clients of various Wellington investment advisers, with no single client owning more than 5% of the class.
CG Oncology (CGON) Faces A Fair Value Gap Following Its Latest Earnings
CG Oncology recently reported its Q2 and H1 2026 earnings, showing revenue of US$1.16 million for the quarter and a net loss of US$79.06 million. Despite being a loss-making company, a discounted cash flow (DCF) model by Simply Wall St estimates a fair value of US$542.38 per share, significantly higher than its current trading price of US$76.99, indicating a large potential undervaluation. However, the company still faces risks associated with ongoing losses and multiple late-stage clinical trials.
CGON (NASDAQ: CGON) holder files to sell 32,137 shares after option exercise
An insider at CG Oncology, Ambaw Bellete, has filed to sell 32,137 common shares of CGON through Morgan Stanley Smith Barney LLC. This proposed sale is linked to a stock option exercise on August 12, 2026, with an aggregate market value of over $2.5 million. The filing also disclosed multiple prior open-market sales by Bellete in July and August 2026.
CGON (CGON) insider Ambaw Bellete plans 50,000-share stock sale
CG Oncology (CGON) insider Ambaw Bellete plans to sell 50,000 shares of common stock on August 11, 2026, through a stock option exercise settled in cash. The estimated value of this planned sale is $3,810,255.00. This disclosure also reveals several recent sales of CGON common stock by Ambaw Bellete, totaling over 290,000 shares, between July 15 and August 10, 2026, with significant dollar values.
CG Oncology (NASDAQ:CGON) Hits New 52-Week High - Should You Buy?
CG Oncology (NASDAQ:CGON) recently reached a new 52-week high of $77.49, with a current trading price near $76.98. The clinical-stage biopharmaceutical company has a "Moderate Buy" consensus rating from analysts, with several price target increases, but reported a quarterly loss of $0.90 per share, missing estimates. Insider selling also occurred, with directors offloading shares totaling approximately $2.66 million in the last quarter.
CGON (CGON) insider plans 50,000-share stock sale after option exercise
CG Oncology, Inc. (CGON) filed a Form 144 indicating an insider's plan to sell 50,000 shares of common stock, valued at $3,770,580.00, on August 10, 2026, following a stock option exercise. The filing also details previous common stock sales by Ambaw Bellete over the past three months, including significant transactions in early August 2026. This activity relates to transparent regulatory filings regarding large stock sales.
HC Wainwright Has Weak Estimate for CG Oncology Q3 Earnings
HC Wainwright has lowered its Q3 2026 EPS estimate for CG Oncology (NASDAQ:CGON) to a loss of $0.96 per share from a previous loss estimate of $0.78, while maintaining a "Buy" rating and $100 price target. This revision follows CG Oncology's latest quarterly results, where the company reported a $0.90-per-share loss, missing the $0.66 consensus estimate, despite revenue of $1.16 million exceeding forecasts of $0.36 million. Analyst sentiment remains largely positive, with a "Moderate Buy" consensus rating and an average price target of $83.18, although some analysts have adjusted their targets or ratings.
Bank of America Securities Reaffirms Their Buy Rating on CG Oncology, Inc. (CGON)
Bank of America Securities reiterated a Buy rating on CG Oncology, Inc. (CGON) with an $88.00 price target. This affirmation follows the company's Q2 earnings report, which showed $1.16 million in revenue and a net profit of $0, a significant improvement from the prior year's net loss. Insider sentiment for CGON is positive, with notable share purchases by a director.
Enterprise value to EBITDA forward of CG Oncology, Inc. – NASDAQ:CGON
This page from TradingView provides financial information for CG Oncology, Inc. (NASDAQ: CGON), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed at the time of viewing and presents various navigation options related to markets, products, and community features of the TradingView platform.
Bank of America Corp DE Grows Holdings in CG Oncology, Inc. $CGON
Bank of America Corp DE increased its stake in CG Oncology, Inc. by 21.8% in the first quarter, bringing its total holdings to 1.45 million shares valued at approximately $98.1 million. Institutional investors now own 26.56% of the company's stock, while insider transactions show mixed activity with significant purchases by one director and sales by another. Analysts maintain a "Moderate Buy" consensus with an average price target of $83.18, despite the company reporting a wider-than-expected quarterly loss of $0.90 per share, though revenue surpassed estimates.
CG Oncology (NASDAQ:CGON) Posts Earnings Results, Misses Expectations By $0.24 EPS
CG Oncology (NASDAQ:CGON) reported a wider-than-expected quarterly loss of $0.90 per share, missing consensus estimates by $0.24, despite revenue of $1.16 million surpassing expectations. The stock saw a slight increase to $75.10, near its 52-week high, and maintains a "Moderate Buy" consensus rating with an average price target of $83.18. However, insider selling worth $2.66 million and a lowered intermediate-term earnings forecast by one analyst present a mixed outlook alongside positive analyst sentiment and increased institutional ownership.
Insider Ambaw Bellete plans CGON (CGON) stock sale after large prior trades
Ambaw Bellete, an insider at CG Oncology, Inc. (CGON), has filed a Form 144 indicating an intent to sell up to 9,250 shares of common stock on August 7, 2026, through Morgan Stanley Smith Barney LLC. This filing also details several significant common stock sales by Bellete in the preceding three months, including transactions on August 6th, August 5th, and July 15th, 2026. The Form 144 provides transparency on planned stock sales and recent trading activities by company insiders.
How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data
CG Oncology recently reported a wider quarterly loss of US$79.06 million, despite generating US$1.16 million in revenue. This financial performance contrasts with promising Phase 3 data for its bladder cancer treatment, cretostimogene grenadenorepvec, which met its primary endpoint. The article discusses how investors are weighing the company's cash-burning status and financing risk against its strong clinical progress and upcoming regulatory milestones for its key drug.
BofA Adjusts Price Target on CG Oncology to $88 From $87
BofA Securities has raised its price target for CG Oncology (CGON) shares to $88 from $87, while maintaining a Buy rating. This adjustment follows a previous price target revision by RBC, which lowered its target to $79 from $81. The article highlights recent news regarding CG Oncology, including Q2 earnings results and progress in its clinical trials for bladder cancer treatments.
Press Release: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates
This press release details CG Oncology's financial results for the second quarter of 2026 and provides key business updates. It covers the company's financial performance, including revenue and expenses, alongside progress on its pipeline and strategic initiatives.
How Investors Are Reacting To CG Oncology (CGON) Wider Quarterly Loss Amid Promising Phase 3 Bladder Cancer Data
CG Oncology recently reported a wider net loss of US$79.06 million in Q2 2026, while generating US$1.16 million in revenue. Despite the financial setback, the company is advancing its lead drug, cretostimogene grenadenorepvec, for non-muscle invasive bladder cancer, with promising Phase 3 data published in The Lancet Oncology. The article discusses how investors are balancing the widening losses with the strong clinical data and upcoming regulatory milestones, highlighting the tension between the company's cash-burning status and its potential for a commercially relevant therapy.
CG Oncology, Inc. Stock 12‑Month Price Target Raised to $91.15, Implies 26% Upside
CG Oncology, Inc.'s average 12-month stock price target has increased from $90.69 to $91.15, based on estimates from 13 analysts, suggesting a 26% potential upside from its August 5 closing price. The consensus rating for CGON remains a "Buy" among 15 analysts, with 14 recommending a buy and 1 recommending a hold.
Insider (NASDAQ: CGON) files to sell 75,000 shares after recent stock sales
Ambaw Bellete, an insider at CG Oncology, Inc. (NASDAQ: CGON), has filed to sell 75,000 shares of common stock through Morgan Stanley's Executive Financial Services program, linked to a stock option exercise on August 6, 2026. This proposed sale has an aggregate market value of $5,672,212.50. The filing also details multiple prior stock sales by Bellete over the past three months, with significant dollar values, indicating a pattern of recent disposals.
CG Oncology earnings up next amid bladder cancer therapy push By Investing.com
CG Oncology Inc. is set to report second-quarter earnings, with analysts expecting a narrower loss as the company progresses towards a regulatory filing for its bladder cancer treatment. The biotech aims to complete its Biologics License Application by Q4 2026, positioning it for potential FDA approval next year. Investors will be focused on the regulatory timeline, competitive data, ongoing trial updates, and the company's cash burn.
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
CG Oncology, Inc. (CGON) reported a Q2 loss of $0.9 per share, missing the Zacks Consensus Estimate of a $0.7 loss, and posted revenues of $1.16 million, which fell short of estimates by 59.02%. Despite the earnings miss, the company's shares have risen 74.4% year-to-date, significantly outperforming the S&P 500. The stock currently holds a Zacks Rank #3 (Hold) based on its mixed estimate revisions trend.
